Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neck Carcinoma Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Brachytherapy, Carboplatin, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
926 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
315
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced May 22, 2026, 3:50 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Cabozantinib, Pembrolizumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
Interventions
CDX-527
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
EF5
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced May 22, 2026, 3:50 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Head and Neck Carcinoma, Head and Neck Neoplasm, Salivary Gland Neoplasms, Thyroid Gland Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 22, 2026, 3:50 AM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Low-Risk BCC Excisional Margins
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Bensalem, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced May 22, 2026, 3:50 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions
CP-383
Drug
Lead sponsor
Tasca Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gene therapy, interleukin-2 gene, methotrexate
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Atezolizumab, Tiragolumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Tallahassee, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Oropharyngeal Cancer, Human Papillomavirus
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced May 22, 2026, 3:50 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Adjuvant hypofractionation, Definitive Hypofractionation
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
70 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced May 22, 2026, 3:50 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Recurrent Nasopharynx Carcinoma
Interventions
Etoposide phosphate, Carboplatin, Ifosfamide, Autologous Stem Cell Transplantation
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
2 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced May 22, 2026, 3:50 AM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Malignant Head and Neck Neoplasm
Interventions
Medical Device Qardio® smart scale Usage and Evaluation, Questionnaire Administration
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Rockville, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced May 22, 2026, 3:50 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Malignant Melanoma, Esophageal Squamous Cell Carcinoma
Interventions
RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody)
Biological · Drug
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Nasopharyngeal Carcinoma
Interventions
Nivolumab, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Sue Yom
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer
Interventions
erlotinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced May 22, 2026, 3:50 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Medical Chart Review, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions
recombinant interferon alfa, isotretinoin
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
6
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2011 · Synced May 22, 2026, 3:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Medullary Thyroid Carcinoma
Interventions
Bortezomib, Vandetanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced May 22, 2026, 3:50 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
Interventions
MIT-001 plus CCRT
Drug
Lead sponsor
MitoImmune Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Gilbert, Arizona • Los Angeles, California • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced May 22, 2026, 3:50 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, cisplatin, paclitaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
216
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced May 22, 2026, 3:50 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Papillary Thyroid Cancer, Papillary Thyroid Microcarcinoma
Interventions
RFA
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced May 22, 2026, 3:50 AM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Diffusion-weighted imaging magnetic resonance imaging, FDG PET/CT
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 3:50 AM EDT